Alumis Says Phase 2 Trial of Envudeucitinib in Lupus Misses Goals in Overall Trial Population

MT newswire2026/09/01 12:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

08:10 AM EDT, 09/01/2026 (MT Newswires) -- Alumis (ALMS) said Tuesday a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population. The company said a pre-specified subgroup of patients with high interferon gene signature showed "robust" responses that could support a path forward for regulatory engagement on a phase 3 study. Alumis said the IFNGS-high group was under-represented in the trial, which affected the overall results. The company said it plans to engage regulators to discuss phase 3 development of envudeucitinib in lupus erythematosus, while it remains on track to file a new drug application in Q4 for envudeucitinib in moderate-to-severe plaque psoriasis.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41